VIR BIOTECHNOLOGY INC (VIR) Forecast, Price Target & Analyst Ratings

NASDAQ:VIR • US92764N1028

Current stock price

10.37 USD
+0.02 (+0.19%)
At close:
10.37 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for VIR BIOTECHNOLOGY INC (VIR).

Forecast Snapshot

Consensus Price Target

Price Target
$21.19
+ 104.37% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.10
Revenue Estimate
110.38M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.29%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$21.19
Upside
+ 104.37%
From current price of $10.37 to mean target of $21.19, Based on 14 analyst forecasts
Low
$17.17
Median
$20.40
High
$31.50

Price Target Revisions

1 Month
28.85%
3 Months
24.05%

Price Target Summary

14 Wall Street analysts provided a forecast for the next 12 months for VIR. The average price target is 21.19 USD. This implies a price increase of 104.37% is expected in the next year compared to the current price of 10.37.
The average price target has been revised upward by 24.05% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

VIR Current Analyst RatingVIR Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8

Analyst Ratings History

VIR Historical Analyst RatingsVIR Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 2 4 6 8 10

Analyst Ratings Consensus

ChartMill Buy Consensus
84.29%
VIR was analyzed by 14 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about VIR.
In the previous month the buy percentage consensus was at a similar level.
VIR was analyzed by 14 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-03-04HC Wainwright & Co.Maintains Buy -> Buy
2026-02-25BarclaysMaintains Overweight -> Overweight
2026-02-24NeedhamMaintains Buy -> Buy
2026-02-24Evercore ISI GroupMaintains Outperform -> Outperform
2026-02-24Morgan StanleyMaintains Overweight -> Overweight
2026-02-09NeedhamReiterate Buy -> Buy
2025-12-30HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-15HC Wainwright & Co.Reiterate Buy -> Buy
2025-09-03Evercore ISI GroupInitiate Outperform
2025-08-27B of A SecuritiesUpgrade Neutral -> Buy
2025-07-11Raymond JamesInitiate Outperform
2025-05-22NeedhamReiterate Buy -> Buy
2025-05-12NeedhamMaintains Buy -> Buy
2025-04-17Goldman SachsMaintains Buy -> Buy
2025-02-28BarclaysMaintains Overweight -> Overweight
2025-02-28HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-27NeedhamReiterate Buy -> Buy
2025-01-31HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-13Leerink PartnersMaintains Outperform -> Outperform
2025-01-10HC Wainwright & Co.Reiterate Buy -> Buy
2025-01-09JP MorganMaintains Neutral -> Neutral
2025-01-09Morgan StanleyUpgrade Equal-Weight -> Overweight
2024-11-20NeedhamReiterate Buy -> Buy
2024-11-20HC Wainwright & Co.Reiterate Buy -> Buy
2024-11-04BarclaysMaintains Overweight -> Overweight

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.10
Revenue Estimate
110.38M
Revenue Q2Q
3,540.50%
EPS Q2Q
89.05%
Number of Analysts
11

Next Earnings Revisions

Revenue (1 Month)
5,474.75%
Revenue (3 Months)
4,561.32%
EPS (1 Month)
20.00%
EPS (3 Months)
85.80%

Next Earnings Summary

VIR is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.1 USD and the consensus revenue estimate is 110.38M USD.
The next earnings revenue estimate has been revised upward by 4561.32% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
VIR revenue by date.VIR revenue by date.
86.18M
-94.67%		74.205M
-13.90%		68.556M
-7.61%		253.81M
270.22%		102.48M
-59.62%		159.49M
55.63%		234.77M
47.20%		327.88M
39.66%		510.74M
55.77%		828.88M
62.29%		1.208B
45.74%
EBITDA
YoY % growth
VIR ebitda by date.VIR ebitda by date.
-664.854M
-179.16%		-537.611M
19.14%		-467.83M
12.98%		-299.808M
35.92%		-373.119M
-24.45%		-323.995M
13.17%		-268.665M
17.08%		-140.158M
47.83%		-43.955M
68.64%		42.269M
196.16%		227.47M
438.15%
EBIT
YoY % growth
VIR ebit by date.VIR ebit by date.
-684.305M
-182.14%		-552.17M
19.31%		-479.51M
13.16%		-369.521M
22.94%		-389.497M
-5.41%		-303.59M
22.06%		-306.094M
-0.82%		-147.686M
51.75%		20.907M
114.16%		303.96M
1,353.87%		589.77M
94.03%
Operating Margin
VIR operating margin by date.VIR operating margin by date.
-794.04%-744.11%-699.44%-145.59%-380.07%-190.35%-130.38%-45.04%4.09%36.67%48.82%
EPS
YoY % growth
VIR eps by date.VIR eps by date.
-4.59
-220.47%		-3.82
16.78%		-3.16
17.28%		-2.14
32.19%		-2.33
-8.68%		-1.73
25.92%		-1.01
41.65%		-0.80
20.74%		0.08
110.13%		1.35
1,568.75%		2.58
91.39%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.10
89.05%		-0.55
31.28%		-0.79
32.66%		-0.73
-135.59%		-0.35
-260.24%		-0.62
-12.87%		-0.57
27.15%		-0.59
19.24%		-0.56
-60.04%		-0.56
10.47%		-0.26
54.25%		-0.24
58.90%
Revenue
Q2Q % growth		110.38M
3,540.50%		68.21M
5,518.62%		1.298M
440.83%		54.618M
-14.75%		50.813M
-53.97%		16.473M
-75.85%		313.1K
-75.88%		313.1K
-99.43%		313.1K
-99.38%		313.1K
-98.10%		55.863M
17,741.90%		60.307M
19,161.26%
EBITDA
Q2Q % growth		-126.809M
7.23%		-119.31M
-5.77%		-119.482M
27.44%		-114.788M
-216.74%		-40.794M
67.83%		-75.467M
36.75%		-89.607M
25.00%		-88.516M
22.89%		-90.173M
-121.04%		-92.334M
-22.35%		-50.934M
43.16%		-48.591M
45.10%
EBIT
Q2Q % growth		-68.297M
51.06%		-119.068M
-0.40%		-123.606M
28.73%		-126.33M
-163.62%		-43.43M
36.41%		-76.558M
35.70%		-91.546M
25.94%		-90.395M
28.45%		-92.284M
-112.49%		-93.213M
-21.75%		-52.48M
42.67%		-50.086M
44.59%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

VIR Yearly Revenue VS EstimatesVIR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
VIR Yearly EPS VS EstimatesVIR Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
13.29%
EPS Next 5 Year
11.81%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
101.79%
Revenue Next 5 Year
76.01%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
10.75%
EBIT Next 5 Year
11.49%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

VIR BIOTECHNOLOGY INC / VIR Forecast FAQ

Can you provide the average price target for VIR BIOTECHNOLOGY INC stock?

14 analysts have analysed VIR and the average price target is 21.19 USD. This implies a price increase of 104.37% is expected in the next year compared to the current price of 10.37.

When does VIR BIOTECHNOLOGY INC (VIR) report earnings?

VIR BIOTECHNOLOGY INC (VIR) will report earnings on 2026-05-06.

What are the consensus estimates for VIR stock next earnings?

The consensus EPS estimate for the next earnings of VIR BIOTECHNOLOGY INC (VIR) is -0.1 USD and the consensus revenue estimate is 110.38M USD.

How many analysts have analysed VIR BIOTECHNOLOGY INC (VIR)?

The number of analysts covering VIR BIOTECHNOLOGY INC (VIR) is 14.